Humanized Mouse Model Market Share, Trends & Analysis

Q: What Was the Historical Outlook of the Market?

From 2017 to 2022, the market recorded a 5.3% HCAGR. Read Report

Humanized Mouse Model Market Outlook 2023 to 2033

The global humanized mouse model market size is projected to be worth US$ 101.5 million in 2023. The humanized mouse model market forecasts growth from 2023 to 2033 of 5.8% CAGR to reach US$ 178.3 million.

One of the main drivers of increased research activities in humanized mouse models is the rising demand from the healthcare sector for more thorough screening of novel drug candidates discovered to treat various chronic diseases such as cardiovascular conditions, diabetes, and cancers. From 2017 to 2022, the global humanized mouse and rat model market experienced a CAGR of 5.3%.

Key Market Highlights

Using genetically engineered mice in experimental medical research has significantly advanced the understanding of illness and human health.
With the development of gene targeting, transgenics, and recent advancements in gene-editing techniques, the manipulation of the mouse genome has improved.
More complex models can be made, owing to improvements in genetic engineering techniques, which may increase the usefulness of these models in the research and development of new drugs.
As a trustworthy tool for preclinical research, mouse models' utility in predicting gene function is constrained by this divergence.
Mice and humans share many genetic traits, although it is also recognized that even very slight sequence differences can have a functional impact on the specific gene functions of each species.

Attributes	Details
Humanized Mouse Model Market Value for 2023	US$ 101.5 million
Humanized Mouse Model Market Value for 2033	US$ 178.3 million
Humanized Mouse Model Market CAGR from 2023 to 2033	5.8%

Don't pay for what you don't need

Customize your report by selecting specific countries or regions and save 30%!

A Deep Dive From 2018 to 2022 and a Vision From 2023 to 2033 For Humanized Mouse Model Market

The humanized mouse model demand increased steadily between 2017 and 2022, accelerated by increased research into infectious illnesses, cancer, and immunology. These models were frequently utilized by academic institutions and pharmaceutical corporations for preclinical research, creating a stable humanized mouse model market.

Historical CAGR	5.3%
Forecast CAGR	5.8%

The humanized mouse and rat model market is expected to strengthen significantly between 2023 and 2033. The introduction of customized medicine, increased investment in drug research, and an increasing focus on precision medicines are just a few of the factors that have contributed to this surge. The adoption is fueled by the need for trustworthy preclinical models replicating human physiology.

The humanized mice model market is anticipated to have significant expansion, which reflects the dynamic environment of biomedical research and medication development. Several genes have been discovered in humans but have not been discovered in their orthologous mouse counterparts.

These genetically humanized mice can offer more trustworthy in vivo information regarding human gene function in healthy physiology and disease. As a result, creating genetically modified mice that express an orthologous human gene is becoming increasingly popular.

DRIVERS

An increase in the need for individualized medication.
Government and corporate sector initiatives and ongoing support for cancer research.
Expanding research and development in the biotechnology and pharmaceutical industries.

RESTRAINTS

Custom humanized models are expensive.
Legislation and rules governing the ethical use of animal models in research.

OPPORTUNITY

Escalating the need for PDX models that have been given human characteristics.
The development of CRISPR as a potent tool for biomedical research.
Growing demand for models using humanized rats.

CHALLENGES

Other options for using animals in testing.
Using humanized mouse models has some drawbacks.

Personalized Medicine Acts as A Catalyst for Market Growth for Humanized Mouse Model

Individual biomarkers are used to customize therapies in precision medicine, also known as personalized medicine. Researchers used mice to generate a PDX model for cancer by injecting immune-compromised mice with patient tumor components. Every mouse undergoes a different course of treatment, shaping patients' distinctive tumor-reduction plans.

The demand for individualized medication is set to rise with the adoption of humanized mouse models. Acute myeloid leukemia (AML) and bladder, breast, lung, pancreatic, and ovarian malignancies are just a handful of the illnesses for which Jackson Laboratory has developed more than 450 different PDX oncology mice models.

As a result of advancements in scientific research, associated tools, and technologies, customized medicine has advanced more quickly. These factors are anticipated to fuel humanized mouse model market expansion during the upcoming years.

Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Humanized Mouse Models are a Key Asset in Pharmaceutical Research for Safer Medications

Humanized mouse models play an integral part in discovering new drugs by providing a crucial link between laboratory research and clinical trials. These models closely resemble how people react to medications because they have immune systems and genetic makeup similar to humans. This allows researchers to evaluate the safety and efficacy of new treatments during the preclinical stages with more accuracy.

This accuracy lowers the possibility of negative outcomes in subsequent clinical studies, saving time and dollars for pharmaceutical companies. The humanized mouse model market stands to gain greatly due to the continued need for better preclinical models to advance drug development pipelines. These models are crucial in the ongoing search for safer and more potent medications.

Competitive Alternatives Stifles the Humanized Mice Model Market Advancement

Researchers are searching for alternatives to conventional models for human study due to increasing humanized mouse model demand from animal rights organizations to discontinue using animals for experimentation. The use of animals for testing has drawbacks, such as the demand for specialized personnel, protracted protocols, and expensive expenses. The study of diabetes uses various methods and non-traditional species, such as rapid computer simulations, artificial blood vessel testing systems, and cell culture techniques for medication investigation.

In vitro testing techniques, online patient drug registries, simulating virtual drug trials, non-invasive imaging techniques including magnetic resonance imaging (MRI) and computed tomography (CT) scans, micro-dosing, and other options are some newer possibilities.

The development of these techniques can affect how humanized mouse models are used as researchers attempt to reduce the price of drug testing. Non-animal-tested products may rise due to marketing that positions them as environmentally beneficial. These factors are anticipated to restrain the humanized mouse model market expansion throughout the forecasted period.

Category-wise Outlook

Genetic Humanized Mouse Models Segment Takes Center Stage

It is anticipated that the genetic humanized mouse models segment is going to dominate the market. This dominance is primarily related to the extensive use of genetically humanized mouse models in various experimental investigations, notably when evaluating the efficacy and safety of substances. The growing use of these mouse models to study medication metabolism and disposition boosts the humanized mouse model market revenue growth.

Leading Segment	Segment Share
Genetic Humanized Mice Model	53.3%

The significance of the genetically humanized mouse model segment is attributed to its critical contribution to accelerating drug discovery and development. Genetic humanized mouse models continue to be actively utilized by pharmaceutical and biotechnology businesses and research organizations, solidifying their position as the industry's significant source of revenue for experimental analysis and drug development.

Oncology's Dominance in the Humanized Mouse Model Industry

Leading the humanized mouse model market expansion is the oncology section, which takes the lead. To understand the biology of cancer, create new treatments, and assess the effectiveness of medications, oncology research mainly relies on humanized mouse models. These models enable more precise and trustworthy preclinical research by simulating the human tumor microenvironment.

Leading Segment	Segment Share
Oncology	33.2%

Due to a pressing demand for cutting-edge cancer research and treatment development, the oncology section takes the lead. The demand for humanized mouse models in this research is anticipated to be strong as long as cancer remains a problem for the world's health, promoting advancement and innovation in cancer therapies.

Academic & Research Institutions Segment Spur Humanized Mouse Model Demand

Academic and Research Institutions are the main humanized mouse model demand generators. These organizations are at the bleeding edge of cutting-edge scientific research. They are actively involved in the investigation of numerous diseases, the creation of new medications, and the testing of new therapeutics. The evaluation of innovative treatments and the comprehension of disease mechanisms are made possible using humanized mouse models in preclinical investigations by academic and research institutes.

Leading Segment	Segment Share
Academic & Research Institutes	43.9%

Companies in the pharmaceutical and biotechnology industries and contract research organizations considerably contribute to the rat and mouse model market expansion. These organizations use humanized mouse models to speed up drug discovery and development, resulting in faster market entry of safer and more potent pharmaceuticals. The humanized mouse model market’s variety of end-user categories underscores the crucial role that humanized mouse models have played in improving both therapeutic innovation and medical research.

Region-wise Analysis

Promising Growth Prospects of North America's Humanized Mouse Model Market

The humanized mouse model market in North America is anticipated to expand significantly. The demand for customized medicine contributes to the trend, and medication development requires using humanized mouse models for preclinical research. Improvements in genetic engineering and genome editing methods have facilitated the creation of humanized mice models that are more precise and pertinent.

Attributes	Details
North America Market Share	41.4%
United States Market Share	32.6%

In North America, pharmaceutical firms and academic institutions increasingly use these models to examine human diseases and evaluate potential treatments. The region's strong healthcare system and significant financial commitments to biomedical research play a role in the rat and mouse model market in North America's promising future.

Gene Editing and Precision Medicine Fuel Market Growth in Europe

Due to its critical contribution to advancing biomedical research and drug discovery, the European rat and mouse model market has a positive outlook. The adoption of humanized mouse models is being boosted by this region's dedication to cutting-edge research and healthcare innovation, allowing for more precise disease modeling and preclinical testing. Developments in gene editing technologies have significantly enhanced the accuracy and applicability of these models.

Attributes	Details
Europe Market Share	33.4%
Germany Market Share	7.9%
United Kingdom Market CAGR	5.9%

Humanized mouse models are used more frequently by European pharmaceutical corporations and academic institutions to study diseases, assess prospective treatments, and create customized medicine methods. The European humanized mouse model market benefits from a strong healthcare infrastructure and significant investments in the life sciences industry, strengthening its position as a center for creating humanized mouse models.

Asia Pacific's Scientific Innovation is a Promising Path for Humanized Mouse Models

The Asia Pacific humanized mouse model market is expected to grow rapidly in the future years. The region's booming pharmaceutical and biotechnology companies and a growing emphasis on precision medicine are propelling the use of humanized mouse models for preclinical research. Advances in genetic engineering and genome editing techniques have created more sophisticated and relevant models, increasing their utility in disease modeling and medication testing.

Attributes	Details
India Market CAGR	5.8%
China Market CAGR	7.0%
Japan Market Share	4.1%

In Asia Pacific, academic institutions, research organizations, and pharmaceutical corporations progressively incorporate these models into their research workflows. The Asia Pacific is emerging as a leading global humanized mouse model market player. It has substantial potential for innovation and scientific development due to a growing healthcare infrastructure and increased investments in life sciences.

Competitive Analysis

Due to the rising need for preclinical research tools in immunology and drug development, the humanized mouse model industry has a dynamic and varied competitive environment. These businesses use genetic modification methods like CRISPR/Cas9 to create customized mouse models and provide a wide range of humanized mouse models and related services.

Collaborations with pharmaceutical and biotechnology companies for illness modeling and medication testing accelerate competition. Emerging humanized mouse model manufacturers break into the industry, encouraging innovation and healthy competition.

Recent Paradigm Shifts

Company	Taconic Biosciences
Details	The huNOG-EXL EA humanized immune system (HIS) mouse was introduced in January 2022 by Taconic Biosciences, a leader in providing drug research animal model solutions. Taconic's widely utilized HIS portfolio is widened with this offering. The study window in which a myeloid-lineage HIS mouse model can be successfully used is greatly extended by huNOG-EXL EA.

Company	genOway
Details	Axenis, a firm committed to the creation of immunocompromised models for the validation of novel and innovative therapies, was acquired by genOway, a biotechnology company focused on the design and development of preclinical models, in September 2021.

Company	The Jackson Laboratory
Details	The Jackson Laboratory (JAX), a nonprofit biomedical research organization, announced in October 2021 that it has acquired the Research Models & Services (RMS) division of Charles River Laboratories Japan as a wholly owned subsidiary. The Jackson Laboratory Japan, a company based in Japan, has about 250 workers, three production facilities in Atsugi, Hino, and Tsukuba, as well as an administrative office in Yokohama.

Company

The Jackson Laboratory

Details

The Jackson Laboratory (JAX), a nonprofit biomedical research organization, announced in October 2021 that it has acquired the Research Models & Services (RMS) division of Charles River Laboratories Japan as a wholly owned subsidiary. The Jackson Laboratory Japan, a company based in Japan, has about 250 workers, three production facilities in Atsugi, Hino, and Tsukuba, as well as an administrative office in Yokohama.

Prominent Humanized Mouse Model Manufacturers

Ingenious Targeting Laboratory
Axenis S.A.S
Trans Genic Inc.
Horizon Discovery Group PLC
HuMurine Technologies
Champions Oncology Inc.
Genoway S.A.
Crown Bioscience Inc.
Taconic Biosciences Inc.
The Jackson Laboratory
Vitalstar Biotechnology Co. Ltd.

Key Segments

By Model Type:

Genetic
Cell-based
- CD34
- PBMC
- BLT

By Application:

Oncology
Immunology and Infectious Diseases
Neuroscience
Toxicology
Hematopoiesis
Other Applications

By End User:

Pharmaceutical & Biotechnology Companies
Contract Research Organizations
Academic & Research Institutions

By Region:

North America
Europe
Asia Pacific
The Middle East & Africa
Latin America

Frequently Asked Questions

What is the Current Humanized Mouse Model Market Valuation?

The humanized mouse model market to secure a valuation of US$ 101.5 million in 2023.

How Big Can the Humanized Mouse Model Market Be by 2033?

The humanized mouse model market is estimated to reach US$ 178.3 million by 2033.

What is the Growth Potential of the Market?

Through 2033, the market is anticipated to expand at a 5.8% CAGR.

What Was the Historical Outlook of the Market?

From 2017 to 2022, the market recorded a 5.3% HCAGR.

Which Model Type Segment to Dominate in the Market?

The genetic humanized mice model sector is set to achieve a market share of 53.3%.

Which End-user Segment to Lead the Humanized Mouse Model Market?

A 43.9% mice model market share is expected for the academic & research institutes sector.

What is the Growth Outlook of China Market?

The China humanized mouse and rat model market to exhibit a CAGR of 7.0% through 2033.

Table of Content

1. Executive Summary
1.1. Global Market Outlook
1.2. Demand-side Trends
1.3. Supply-side Trends
1.4. Technology Roadmap Analysis
1.5. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
3. Market Background
3.1. Market Dynamics
3.1.1. Drivers
3.1.2. Restraints
3.1.3. Opportunity
3.1.4. Trends
3.2. Scenario Forecast
3.2.1. Demand in Optimistic Scenario
3.2.2. Demand in Likely Scenario
3.2.3. Demand in Conservative Scenario
3.3. Opportunity Map Analysis
3.4. Product Life Cycle Analysis
3.5. Supply Chain Analysis
3.5.1. Supply Side Participants and their Roles
3.5.1.1. Producers
3.5.1.2. Mid-Level Participants (Traders/ Agents/ Brokers)
3.5.1.3. Wholesalers and Distributors
3.5.2. Value Added and Value Created at Node in the Supply Chain
3.5.3. List of Raw Material Suppliers
3.5.4. List of Existing and Potential Buyer’s
3.6. Investment Feasibility Matrix
3.7. Value Chain Analysis
3.7.1. Profit Margin Analysis
3.7.2. Wholesalers and Distributors
3.7.3. Retailers
3.8. PESTLE and Porter’s Analysis
3.9. Regulatory Landscape
3.9.1. By Key Regions
3.9.2. By Key Countries
3.10. Regional Parent Market Outlook
3.11. Production and Consumption Statistics
3.12. Import and Export Statistics
4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033
4.1. Historical Market Size Value (US$ Million) & Volume (Units) Analysis, 2018 to 2022
4.2. Current and Future Market Size Value (US$ Million) & Volume (Units) Projections, 2023 to 2033
4.2.1. Y-o-Y Growth Trend Analysis
4.2.2. Absolute $ Opportunity Analysis
5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Model Type
5.1. Introduction / Key Findings
5.2. Historical Market Size Value (US$ Million) & Volume (Units) Analysis By Model Type, 2018 to 2022
5.3. Current and Future Market Size Value (US$ Million) & Volume (Units) Analysis and Forecast By Model Type, 2023 to 2033
5.3.1. Genetic
5.3.2. Cell-based
5.3.2.1. CD34
5.3.2.2. PBMC
5.3.2.3. BLT
5.4. Y-o-Y Growth Trend Analysis By Model Type, 2018 to 2022
5.5. Absolute $ Opportunity Analysis By Model Type, 2023 to 2033
6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Application
6.1. Introduction / Key Findings
6.2. Historical Market Size Value (US$ Million) & Volume (Units) Analysis By Application, 2018 to 2022
6.3. Current and Future Market Size Value (US$ Million) & Volume (Units) Analysis and Forecast By Application, 2023 to 2033
6.3.1. Oncology
6.3.2. Immunology and Infectious Diseases
6.3.3. Neuroscience
6.3.4. Toxicology
6.3.5. Hematopoiesis
6.3.6. Others
6.4. Y-o-Y Growth Trend Analysis By Application, 2018 to 2022
6.5. Absolute $ Opportunity Analysis By Application, 2023 to 2033
7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By End User
7.1. Introduction / Key Findings
7.2. Historical Market Size Value (US$ Million) & Volume (Units) Analysis By End User, 2018 to 2022
7.3. Current and Future Market Size Value (US$ Million) & Volume (Units) Analysis and Forecast By End User, 2023 to 2033
7.3.1. Pharmaceutical & Biotechnology Companies
7.3.2. Contract Research Organizations
7.3.3. Academic & Research Institutions
7.4. Y-o-Y Growth Trend Analysis By End User, 2018 to 2022
7.5. Absolute $ Opportunity Analysis By End User, 2023 to 2033
8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region
8.1. Introduction
8.2. Historical Market Size Value (US$ Million) & Volume (Units) Analysis By Region, 2018 to 2022
8.3. Current Market Size Value (US$ Million) & Volume (Units) Analysis and Forecast By Region, 2023 to 2033
8.3.1. North America
8.3.2. Latin America
8.3.3. Western Europe
8.3.4. Eastern Europe
8.3.5. South Asia and Pacific
8.3.6. East Asia
8.3.7. Middle East and Africa
8.4. Market Attractiveness Analysis By Region
9. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
9.1. Historical Market Size Value (US$ Million) & Volume (Units) Trend Analysis By Market Taxonomy, 2018 to 2022
9.2. Market Size Value (US$ Million) & Volume (Units) Forecast By Market Taxonomy, 2023 to 2033
9.2.1. By Country
9.2.1.1. U.S.
9.2.1.2. Canada
9.2.2. By Model Type
9.2.3. By Application
9.2.4. By End User
9.3. Market Attractiveness Analysis
9.3.1. By Country
9.3.2. By Model Type
9.3.3. By Application
9.3.4. By End User
9.4. Key Takeaways
10. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
10.1. Historical Market Size Value (US$ Million) & Volume (Units) Trend Analysis By Market Taxonomy, 2018 to 2022
10.2. Market Size Value (US$ Million) & Volume (Units) Forecast By Market Taxonomy, 2023 to 2033
10.2.1. By Country
10.2.1.1. Brazil
10.2.1.2. Mexico
10.2.1.3. Rest of Latin America
10.2.2. By Model Type
10.2.3. By Application
10.2.4. By End User
10.3. Market Attractiveness Analysis
10.3.1. By Country
10.3.2. By Model Type
10.3.3. By Application
10.3.4. By End User
10.4. Key Takeaways
11. Western Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
11.1. Historical Market Size Value (US$ Million) & Volume (Units) Trend Analysis By Market Taxonomy, 2018 to 2022
11.2. Market Size Value (US$ Million) & Volume (Units) Forecast By Market Taxonomy, 2023 to 2033
11.2.1. By Country
11.2.1.1. Germany
11.2.1.2. U.K.
11.2.1.3. France
11.2.1.4. Spain
11.2.1.5. Italy
11.2.1.6. Rest of Western Europe
11.2.2. By Model Type
11.2.3. By Application
11.2.4. By End User
11.3. Market Attractiveness Analysis
11.3.1. By Country
11.3.2. By Model Type
11.3.3. By Application
11.3.4. By End User
11.4. Key Takeaways
12. Eastern Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
12.1. Historical Market Size Value (US$ Million) & Volume (Units) Trend Analysis By Market Taxonomy, 2018 to 2022
12.2. Market Size Value (US$ Million) & Volume (Units) Forecast By Market Taxonomy, 2023 to 2033
12.2.1. By Country
12.2.1.1. Poland
12.2.1.2. Russia
12.2.1.3. Czech Republic
12.2.1.4. Romania
12.2.1.5. Rest of Eastern Europe
12.2.2. By Model Type
12.2.3. By Application
12.2.4. By End User
12.3. Market Attractiveness Analysis
12.3.1. By Country
12.3.2. By Model Type
12.3.3. By Application
12.3.4. By End User
12.4. Key Takeaways
13. South Asia and Pacific Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
13.1. Historical Market Size Value (US$ Million) & Volume (Units) Trend Analysis By Market Taxonomy, 2018 to 2022
13.2. Market Size Value (US$ Million) & Volume (Units) Forecast By Market Taxonomy, 2023 to 2033
13.2.1. By Country
13.2.1.1. India
13.2.1.2. Bangladesh
13.2.1.3. Australia
13.2.1.4. New Zealand
13.2.1.5. Rest of South Asia and Pacific
13.2.2. By Model Type
13.2.3. By Application
13.2.4. By End User
13.3. Market Attractiveness Analysis
13.3.1. By Country
13.3.2. By Model Type
13.3.3. By Application
13.3.4. By End User
13.4. Key Takeaways
14. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
14.1. Historical Market Size Value (US$ Million) & Volume (Units) Trend Analysis By Market Taxonomy, 2018 to 2022
14.2. Market Size Value (US$ Million) & Volume (Units) Forecast By Market Taxonomy, 2023 to 2033
14.2.1. By Country
14.2.1.1. China
14.2.1.2. Japan
14.2.1.3. South Korea
14.2.2. By Model Type
14.2.3. By Application
14.2.4. By End User
14.3. Market Attractiveness Analysis
14.3.1. By Country
14.3.2. By Model Type
14.3.3. By Application
14.3.4. By End User
14.4. Key Takeaways
15. Middle East and Africa Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
15.1. Historical Market Size Value (US$ Million) & Volume (Units) Trend Analysis By Market Taxonomy, 2018 to 2022
15.2. Market Size Value (US$ Million) & Volume (Units) Forecast By Market Taxonomy, 2023 to 2033
15.2.1. By Country
15.2.1.1. GCC Countries
15.2.1.2. South Africa
15.2.1.3. Israel
15.2.1.4. Rest of MEA
15.2.2. By Model Type
15.2.3. By Application
15.2.4. By End User
15.3. Market Attractiveness Analysis
15.3.1. By Country
15.3.2. By Model Type
15.3.3. By Application
15.3.4. By End User
15.4. Key Takeaways
16. Key Countries Market Analysis
16.1. U.S.
16.1.1. Pricing Analysis
16.1.2. Market Share Analysis, 2022
16.1.2.1. By Model Type
16.1.2.2. By Application
16.1.2.3. By End User
16.2. Canada
16.2.1. Pricing Analysis
16.2.2. Market Share Analysis, 2022
16.2.2.1. By Model Type
16.2.2.2. By Application
16.2.2.3. By End User
16.3. Brazil
16.3.1. Pricing Analysis
16.3.2. Market Share Analysis, 2022
16.3.2.1. By Model Type
16.3.2.2. By Application
16.3.2.3. By End User
16.4. Mexico
16.4.1. Pricing Analysis
16.4.2. Market Share Analysis, 2022
16.4.2.1. By Model Type
16.4.2.2. By Application
16.4.2.3. By End User
16.5. Germany
16.5.1. Pricing Analysis
16.5.2. Market Share Analysis, 2022
16.5.2.1. By Model Type
16.5.2.2. By Application
16.5.2.3. By End User
16.6. U.K.
16.6.1. Pricing Analysis
16.6.2. Market Share Analysis, 2022
16.6.2.1. By Model Type
16.6.2.2. By Application
16.6.2.3. By End User
16.7. France
16.7.1. Pricing Analysis
16.7.2. Market Share Analysis, 2022
16.7.2.1. By Model Type
16.7.2.2. By Application
16.7.2.3. By End User
16.8. Spain
16.8.1. Pricing Analysis
16.8.2. Market Share Analysis, 2022
16.8.2.1. By Model Type
16.8.2.2. By Application
16.8.2.3. By End User
16.9. Italy
16.9.1. Pricing Analysis
16.9.2. Market Share Analysis, 2022
16.9.2.1. By Model Type
16.9.2.2. By Application
16.9.2.3. By End User
16.10. Poland
16.10.1. Pricing Analysis
16.10.2. Market Share Analysis, 2022
16.10.2.1. By Model Type
16.10.2.2. By Application
16.10.2.3. By End User
16.11. Russia
16.11.1. Pricing Analysis
16.11.2. Market Share Analysis, 2022
16.11.2.1. By Model Type
16.11.2.2. By Application
16.11.2.3. By End User
16.12. Czech Republic
16.12.1. Pricing Analysis
16.12.2. Market Share Analysis, 2022
16.12.2.1. By Model Type
16.12.2.2. By Application
16.12.2.3. By End User
16.13. Romania
16.13.1. Pricing Analysis
16.13.2. Market Share Analysis, 2022
16.13.2.1. By Model Type
16.13.2.2. By Application
16.13.2.3. By End User
16.14. India
16.14.1. Pricing Analysis
16.14.2. Market Share Analysis, 2022
16.14.2.1. By Model Type
16.14.2.2. By Application
16.14.2.3. By End User
16.15. Bangladesh
16.15.1. Pricing Analysis
16.15.2. Market Share Analysis, 2022
16.15.2.1. By Model Type
16.15.2.2. By Application
16.15.2.3. By End User
16.16. Australia
16.16.1. Pricing Analysis
16.16.2. Market Share Analysis, 2022
16.16.2.1. By Model Type
16.16.2.2. By Application
16.16.2.3. By End User
16.17. New Zealand
16.17.1. Pricing Analysis
16.17.2. Market Share Analysis, 2022
16.17.2.1. By Model Type
16.17.2.2. By Application
16.17.2.3. By End User
16.18. China
16.18.1. Pricing Analysis
16.18.2. Market Share Analysis, 2022
16.18.2.1. By Model Type
16.18.2.2. By Application
16.18.2.3. By End User
16.19. Japan
16.19.1. Pricing Analysis
16.19.2. Market Share Analysis, 2022
16.19.2.1. By Model Type
16.19.2.2. By Application
16.19.2.3. By End User
16.20. South Korea
16.20.1. Pricing Analysis
16.20.2. Market Share Analysis, 2022
16.20.2.1. By Model Type
16.20.2.2. By Application
16.20.2.3. By End User
16.21. GCC Countries
16.21.1. Pricing Analysis
16.21.2. Market Share Analysis, 2022
16.21.2.1. By Model Type
16.21.2.2. By Application
16.21.2.3. By End User
16.22. South Africa
16.22.1. Pricing Analysis
16.22.2. Market Share Analysis, 2022
16.22.2.1. By Model Type
16.22.2.2. By Application
16.22.2.3. By End User
16.23. Israel
16.23.1. Pricing Analysis
16.23.2. Market Share Analysis, 2022
16.23.2.1. By Model Type
16.23.2.2. By Application
16.23.2.3. By End User
17. Market Structure Analysis
17.1. Competition Dashboard
17.2. Competition Benchmarking
17.3. Market Share Analysis of Top Players
17.3.1. By Regional
17.3.2. By Model Type
17.3.3. By Application
17.3.4. By End User
18. Competition Analysis
18.1. Competition Deep Dive
18.1.1. Ingenious Targeting Laboratory
18.1.1.1. Overview
18.1.1.2. Product Portfolio
18.1.1.3. Profitability by Market Segments
18.1.1.4. Sales Footprint
18.1.1.5. Strategy Overview
18.1.1.5.1. Marketing Strategy
18.1.1.5.2. Product Strategy
18.1.1.5.3. Channel Strategy
18.1.2. Axenis S.A.S
18.1.2.1. Overview
18.1.2.2. Product Portfolio
18.1.2.3. Profitability by Market Segments
18.1.2.4. Sales Footprint
18.1.2.5. Strategy Overview
18.1.2.5.1. Marketing Strategy
18.1.2.5.2. Product Strategy
18.1.2.5.3. Channel Strategy
18.1.3. Trans Genic Inc.
18.1.3.1. Overview
18.1.3.2. Product Portfolio
18.1.3.3. Profitability by Market Segments
18.1.3.4. Sales Footprint
18.1.3.5. Strategy Overview
18.1.3.5.1. Marketing Strategy
18.1.3.5.2. Product Strategy
18.1.3.5.3. Channel Strategy
18.1.4. Horizon Discovery Group PLC
18.1.4.1. Overview
18.1.4.2. Product Portfolio
18.1.4.3. Profitability by Market Segments
18.1.4.4. Sales Footprint
18.1.4.5. Strategy Overview
18.1.4.5.1. Marketing Strategy
18.1.4.5.2. Product Strategy
18.1.4.5.3. Channel Strategy
18.1.5. HuMurine Technologies
18.1.5.1. Overview
18.1.5.2. Product Portfolio
18.1.5.3. Profitability by Market Segments
18.1.5.4. Sales Footprint
18.1.5.5. Strategy Overview
18.1.5.5.1. Marketing Strategy
18.1.5.5.2. Product Strategy
18.1.5.5.3. Channel Strategy
18.1.6. Champions Oncology Inc.
18.1.6.1. Overview
18.1.6.2. Product Portfolio
18.1.6.3. Profitability by Market Segments
18.1.6.4. Sales Footprint
18.1.6.5. Strategy Overview
18.1.6.5.1. Marketing Strategy
18.1.6.5.2. Product Strategy
18.1.6.5.3. Channel Strategy
18.1.7. Genoway S.A.
18.1.7.1. Overview
18.1.7.2. Product Portfolio
18.1.7.3. Profitability by Market Segments
18.1.7.4. Sales Footprint
18.1.7.5. Strategy Overview
18.1.7.5.1. Marketing Strategy
18.1.7.5.2. Product Strategy
18.1.7.5.3. Channel Strategy
18.1.8. Crown Bioscience Inc.
18.1.8.1. Overview
18.1.8.2. Product Portfolio
18.1.8.3. Profitability by Market Segments
18.1.8.4. Sales Footprint
18.1.8.5. Strategy Overview
18.1.8.5.1. Marketing Strategy
18.1.8.5.2. Product Strategy
18.1.8.5.3. Channel Strategy
18.1.9. Taconic Biosciences Inc.
18.1.9.1. Overview
18.1.9.2. Product Portfolio
18.1.9.3. Profitability by Market Segments
18.1.9.4. Sales Footprint
18.1.9.5. Strategy Overview
18.1.9.5.1. Marketing Strategy
18.1.9.5.2. Product Strategy
18.1.9.5.3. Channel Strategy
18.1.10. The Jackson Laboratory
18.1.10.1. Overview
18.1.10.2. Product Portfolio
18.1.10.3. Profitability by Market Segments
18.1.10.4. Sales Footprint
18.1.10.5. Strategy Overview
18.1.10.5.1. Marketing Strategy
18.1.10.5.2. Product Strategy
18.1.10.5.3. Channel Strategy
18.1.11. Vitalstar Biotechnology Co. Ltd.
18.1.11.1. Overview
18.1.11.2. Product Portfolio
18.1.11.3. Profitability by Market Segments
18.1.11.4. Sales Footprint
18.1.11.5. Strategy Overview
18.1.11.5.1. Marketing Strategy
18.1.11.5.2. Product Strategy
18.1.11.5.3. Channel Strategy
19. Assumptions & Acronyms Used
20. Research Methodology

Humanized Mouse Model Market

Humanized Mouse Model Market Forecast by Genetic and Cell-based Model for 2023 to 2033